From the Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut.
Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York.
Anesth Analg. 2022 Sep 1;135(3):460-473. doi: 10.1213/ANE.0000000000006039. Epub 2022 Aug 17.
Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on patient blood management, TXA has become an integral aspect of perioperative blood conservation strategies. While clinical applications of TXA in the perioperative period are expanding, routine use in select clinical scenarios should be supported by evidence for efficacy. Furthermore, questions regarding optimal dosing without increased risk of adverse events such as thrombosis or seizures should be answered. Therefore, ongoing investigations into TXA utilization in cardiac surgery, obstetrics, acute trauma, orthopedic surgery, neurosurgery, pediatric surgery, and other perioperative settings continue. The aim of this review is to provide an update on the current applications and limitations of TXA use in the perioperative period.
氨甲环酸(TXA)是一种强效抗纤维蛋白溶解剂,已被证实可减少多种临床情况下的失血和异体红细胞输血。随着对患者血液管理的重视,TXA 已成为围手术期血液保护策略的一个重要组成部分。虽然 TXA 在围手术期的临床应用正在扩大,但在某些临床情况下常规使用应基于其疗效的证据。此外,还需要解决关于在不增加血栓形成或癫痫等不良事件风险的情况下最佳剂量的问题。因此,目前仍在对 TXA 在心脏手术、产科、急性创伤、骨科手术、神经外科、小儿外科和其他围手术期环境中的应用进行持续研究。本文旨在提供围手术期 TXA 使用的最新应用和局限性的更新。